Institute for Energy Technology – IFE and ONLY Oncology are now members of the Oslo Cancer Cluster.
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 367 entries.
Entries by oslocancer
Cevira® is one of Photocure’s promising pipeline products and is being developed as a new and innovative breakthrough for the treatment of precancerous lesions of the cervix.
-Vi er svært overrasket og skuffet over dagens beslutning om at norske pasienter ikke får tilgang til den nyeste brystkreftmedisinen som allerede er i bruk i de fleste vesteuropeiske land. Roche harstrukket seg langt, både økonomisk og i variasjon av betalingsløsninger, sier kommunikasjonsdirektør Line Walen i Roche Norge.
The EU project will use innovative IT solutions to develop personalized cancer treatment. The EU project will use innovative IT solutions to develop personalized cancer treatment. Allocated funds is 45 million, of which 34 million is earmarked for small and medium enterprises in the clusters.
The interim results indicate promising 1-year overall survival data when combining TG01 with gemcitabine, chemotherapy, as supplementary treatment of patients with pancreatic cancer.
Taskén, who is director of the Biotechnology Centre and the Norwegian Centre for Molecular Medicine (NCMM), receives the award for his work with immunotherapy.
Vaccibody AS announced on March 1 the successful enrolment of all twelve patients required for the phase I part of the multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human papillomavirus 16 (HPV 16).
Oslo Cancer Cluster member Photocure had a great year in 2015 with increased sales. Photocure is a Norwegian specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, listed on the Oslo Stock Exchange.
Nordic Nanovector ASA announces that a late-breaking abstract on its Phase 1/2 clinical study with Betalutin® has been accepted for presentation at the American Association For Cancer Research (AACR) annual meeting.
Curida strengthens its Development Services with a strategic partnership with Dr. René Bommer, who is known for his competency within Nasal Spray and chairs the annual Nasal Drug Delivery conference.
The coverage includes an overview of the cancer treatment being developed by 10 of Oslo Cancer Cluster member companies.
På Verdens kreftdag 4. februar retter Kreftforeningen, Oslo Cancer Cluster og Kreftregisteret søkelyset mot den tause folkesykdommen tarmkreft. Tarmkreftscreening kan redde livet til 300 nordmenn årlig. Det er tre ganger så mange som dør i trafikken hvert år.
The Norwegian Research Council granted Oslo Cancer Cluster member companies Oncoimmunity, Vaccibody, Nextera and Nordic Nanovector funding through the Programme for User-Driven Research Based Innovation (BIA).
Nordic Nanovector receive prestigious BIA funding to support the research and development of novel targeted therapeutics for leukemia and non-Hodgkin Lymphoma.
Oslo Cancer Cluster member and therapeutic vaccine company Vaccibody has received a grant up to NOK 20 million (USD 2.3 million) over four years from the Norwegian Research Council ‘s BIA Program.
Cancer Crosslinks 2016 featured very interesting, cutting-edge presentations from some of the leading cancer clinicians and researchers in the US and Norway. You may download them here or watch some as videos.
The purpose of the collaboration is to utilise the companies’ complementary scientific platforms to explore potential synergies.
PCI Biotech reports that the treatment evaluation of the fourth dose cohort in the Phase I/II study of fimaporfin (Amphinex®) in patients with inoperable bile duct cancer has been completed.
Serviceproduksjon is a subsidary to the Norwegian Pharmace Association. The agreement entails validation of a chemical analytical method for use in analysis of tablets.
Oslo Cancer Cluster had a tremendous growth in the number of members in 2015: 14 new ones joined us. In total the cluster now comprise of 75 members. Please find a short description of our new members from 2015 below.
Cancer Crosslinks 2016 features a really interesting program. For those of you that may not take part of the actual conference in the Oslo Cancer Cluster Innovation Park, you may watch the whole program at your computer as we will live stream from beginning to end.
Oslo Cancer Cluster member Smartfish recently presented that juices containing omega-3, whey proteins and natural antioxidants have beneficial effects on body weight, muscle weight and tumour size in a mouse model for cancer cachexia with or without concomitant chemotherapy.
Thermo Fisher Scientific will rent over 800m2 in the Oslo Cancer Cluster Incubator. Here, the company will create a creative Google-like environment with a particular focus on diagnostics and the development of new treatments using cancer immunotherapy.
Cancer Crosslinks 2016 on January 14 features a really strong program with several renowned international speakers whom have played a major role in developing immunotherapies against cancer. Sign up now.
Oslo Cancer Cluster member Sarsia Seed and Tromsø-based Norinnova have been given the managment of two new national seed capital funds on MNOK 300 in total by the Norwegian government. The money will be matched by privat capital.
The venture session at the DNB Healthcare Conference features three Oslo Cancer Cluster member companies: Lytix Biopharma, Vaccibody and Regencis. They will all present in session five: Therapeutics, that starts at 15:00.
Of the six nominated for the DNB HealthCare Prize on 1 MNOK, two of them are members of the Oslo Cancer Cluster: Vaccibody and Ultimovacs. The other nominees are: Spiro Medical, Glucoset, Picterus and Labrida.
Ludwig Cancer Research and the Cancer Research Institute (CRI) initiate agreement with Oslo Cancer Cluster member Targovax to evaluate its experimental virotherapy, ONCOS-102, in early phase clinical trials.
HealthCap, a leading life science venture capital firm, has opened office in the newly established incubator in the Oslo Cancer Cluster Innovation Park. HealthCap also becomes a member of the Oslo Cancer Cluster.
On November 11 Oslo Cancer Cluster, BMS and MSD arranged the second meeting in the Immuno-Oncology Meeting Series of 2015. You may download the presentations here.
According to The European Biotech News Website, Oslo Cancer Cluster Incubator is the hottest bioincubator in the Nordics as well as the 6th hottest in Europe.
DNB Health Care Conference on December 15th features many of Oslo Cancer Cluster member companies. There will also be a parallel venture session, organised by DNB together with Oslo Medtech, Oslo Cancer Cluster and Nansen Neuro.
February 9th 2016 is the date for the annual Career Day VIVO at NTNU for biology-, chemistry- and biotech students at bachelor and masters.
Centre for Cancer Biomarkers (CCBIO) is a Centre of Excellence at the Faculty of Medicine and Dentistry, University of Bergen. Read their latest news.
February 18 2016 is the date for the annual Career Day at the University of Oslo for students at the Natural Sciences Faculties. Please see more info below.
På vegne av Det Norske Videnskaps-Akademi har vi gleden av å invitere til åpent debattmøte om helseprioriteringer i fremtiden 26. oktober kl 18:15 – 20:00, i Auditoriet på Litteraturhuset i Bergen, Østre Skostredet 5-7. Med bakgrunn i Prioriteringsutvalgets rapport vil debattantene debattere prioriteringer av de begrensede ressursene i norsk helsevesen. Deltagere: Ole Frithjof Norheim, leder […]
January 26.2016 is the date for the annual Career Day at NTNU. Please see more info below on this.
The Minister of Finance Siv Jensen, and the Minister of Trade and Industry, Monica Mæland will be present at the opening to launch a new plan for Norwegian entrepreneurship.
4 Oslo Cancer Cluster member companies will pitch at Norwegian Investment Forum during Oslo Innovation Week Thursday October 15th: Vaccibody, Nordic Nanovector, Regenics and Phoenix Soloutions.
Oslo Cancer Cluster has analyzed the budget in relation to sectors that concern our members.
Åpen innovasjon brer om seg. Hva har det å si for helsevesenet og for de klynger og bedrifter som skaper morgendagens legemidler, helseteknologi og tjenester? Få med deg Open Health Innovation Arena 12. oktober.
The study will investigate the use of Hexvix/Cysview in the outpatient / surveillance setting and is designed to fulfill the FDA post marketing commitments.
DNB Healtcare gives out an Healtcare Award on 1MNOK to Healtcare start-ups.
Oslo Cancer Cluster member Nextera has entered into a research agreement with Janssen Biotech, Inc.
Opportunity for Oslo Cancer Cluster SMB´s: K Teams is a two week, intensive entrepreneurial training program in Boston and Cambridge.
The draft SC1 Work Programme for 2016-17 has been pre-published at https://ec.europa.eu/programmes/horizon2020/en/draft-work-programmes-2016-17.
Vaccibody AS announced today vaccination of the first patient in its multicentre trial VB C-01 – an exploratory, open-label, multicenter phase I/IIa study .
Inven2 is the largest technology transfer company in the Nordic region and a leading actor within Life Science. They now have several therapies and methods to offer within immuno-oncology.
Oslo Cancer Cluster member BerGen BIO awarded Nordic Star at NLS Days2015.
Oslo Cancer Cluster member PCI Biotech has signed an agreement with an undisclosed top-10 large pharma company, with the aim to evaluate synergistic effects of the PCI technology with their therapeutic nucleic acid technology.
Oslo Cancer Cluster Innovation Park´s grand opening on August 24th became a very special day: More than 290 invited guests and a huge media turnout celebrated the initiators Jónas Einarsson and Kaare Norum for turning the radical idea of an oncology innovation park integrating a high school into reality.
PCI Biotech has activated Oslo University Hospital as a new clinical site in the phase I/II study of Amphinex in patients with inoperable bile duct cancer.
NLSDays September 9-10 at Stockholm Waterfront is the Nordic region’s premier life science event.
Oslo Cancer Cluster is hosting a Super Session at the Nordic Life Science Days in Stockholm. International thought leaders will discuss current game changing innovations and their impact on the industry in the years ahead.
The Norwegian Research Council and Norwegian Cancer Society are teaming up to make the results of medical and biotechnical research faster available for cancer patients.
The Norwegian Research Council recently announced four large investments in biomedical research on a total of 255 MNOK.
12 companies will have offices and lab in Oslo Cancer Cluster Incubator from August on. Bjørn Klem, General Manager of the Incubator, anticipates full house by January 2016.
On Thursday June 11 Oslo Cancer Cluster and the Cancer Society of Norway arranged a breakfast meeting on immunotherapy against cancer.
Monday August 24th is the official opening of the Oslo Cancer Cluster Innovation Park. The Prime Minister of Norway, Erna Solberg, will do the honours.
The companies contemplate a private placement of NOK 125–150 million to fund the combined business.
PhD student Marina Vietri and her co-workers in Harald Stenmark’s group at Centre for Cancer Biomedicine and Institute for Cancer Research have uncovered a new cellular mechanism that contributes to keep our genome intact.
Oslo Cancer Cluster member Vaccibody AS wil take part in SAPHIR, a 4 year collaborative research project that has succesfully raised 78 million NOK from the EU Horizon 2020 program.
Oslo Cancer Cluster member Vaccibody secures collaboration funding from the Research Council.
Oslo Cancer Cluster is one of the supporting organizations for this years Nordic Life Science Days in Stockholm: We host an Oncology Super Session and members get discount.
More than 10 Oslo Cancer Cluster members will be present at BIO2015 in Philadelphia in June.
For the 4th year on a row Oslo Cancer Cluster organizes International Cancer Cluster Showcase, ICCS at BIO.
Tilgang til nye kreftmedisiner var tema for seminar på Litteraturhuset 28. april. Du kan se hele møtet i opptak her.
PCI Biotech, a Norwegian cancer focused biopharmaceutical company, announced that it is initiating a pre-clinical research collaboration with RXi Pharmaceuticals (NASDAQ: RXII).
Nordic Nanovector ASA announces the successful completion of the bookbuilding period for its initial public offering, which was multiple times oversubscribed.
Oslo Cancer Cluster is one of the supporting organizations for this years Nodeic Life Science Days in Stockholm, as we were last year. This means that members of the cluster benefit from special rates on participation.
NICE makes evidence-based recommendations for healthcare, with the aim of improving treatment and reducing variations in care.
Mr. Øystein Soug, has been the CFO of the late-stage oncology biotech company Algeta ASA since 2008, building up the functions of Finance, IR, Compliance, IT and HR.
At this years Cancer Crosslinks we made short video interviews with presenters; Professor Paul Baas, Professor Nicholas Navin, Professor Bjørn Tore Gjertsen and professor Kimmo Porkka on their research and views on cancer treatments in the future.
The Norwegian Research Council granted BerGenBio, Lifandis and Smartfish – all Oslo Cancer Cluster member companies – funding from the BIA-programme now.
In a retrospective study Hexvix fluorescence-guided bladder resection significantly improved overall survival and recurrence free survival compared to resection performed with standard white light.
Cancer researchers in Oslo are now using one of the world’s fastest computers to detect which parts of the genetic code may cause bowel and prostate cancer.
February 12, LMI, DNB Healthcare, AbbVie, Novartis and Pfizer hosts a one day seminar called A partnership for life in 2015 – How to develop a strong Norwegian biotechnology and health industry sector?
The technology allows for the development of new and more efficient vaccines as well as new versions of existing vaccines with a need for improved efficacy.
If you missed Cancer Crosslinks, or would like to watch some of the presentations again, here they are.
The funds raised through the share issue will be used to implement and further develop the company’s programme to document the effect of its first product; the therapeutic cancer vaccine UV1.
HORN International is developing the 2nd edition of the book European Biotechnology. Care to join? Oslo Cancer Cluster members receive special offer.
Cancer Crosslinks 2015 is on Thursday January 15. The meeting is fully booked. Follow it on live stream.
The governmental agency SIVA will support the Oslo Cancer Cluster Incubator with MNOK 15 over the next 10 years in order to develop cancer treatment from companies that spins out from strong cancer research.
Photocure ASA, a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces the conclusion of the Phase 2 program, and FDA clearance to prepare Phase 3 protocol for the clinical development of Cevira.
A recent analysis from the audit and advisory company EY is cautiously optimistic on behalf of startup companies in the Nordic Life Science industry – and points to possibilities within Oslo Cancer Cluster.
February 4th is World Cancer Day. Oslo Cancer Cluster will pay tribute to this day by arranging a breakfast meeting at Litteraturhuset together with LMI.
Oslo Cancer Cluster member BerGenBio AS announces that it has raised NOK90 million (c. $15 million) in a private placing from new and existing investors.
Real Karriere will take place February 12 2015. This is the meeting arena for industry and companies and the students within technolgy and natural sciences at the University of Oslo.
In 2012 there were just above 30,000 new cancer cases in Norway. The number of cases is increasing by 1-2 percent each year, so that more than 40,000 cases are expected in 2030.
BerGen Bio, Targovax and Ultimovacs are the winners of the Immuno-Oncology Call 2014. Each company will receive MNOK 0,4 from Innovation Norway.
Nordic Nanovector ASA and Affibody AB have entered into a three-year collaborative research agreement to discover and develop new advanced radio-immunotherapies for multiple myeloma.
Biotechgate welcomes the three Norwegian partners Innovation Norway, Oslo Cancer Cluster and Nansen Neuroscience Network.
Cancer Crosslinks 2015 will be held January 15th at The Institute for Cancer Research at the Norwegian Radium Hospital. The program features several renowned international speakers as well as Norwegian experts. Main theme is “Novel insights into tumor heterogeneity and clonal evolution: how to design treatment and follow-up strategies”. Program and registration form (close […]
Winners will be announced on Oslo Cancer Cluster`s Christmas Meeting December 1st.
Oslo Cancer Cluster members are invited to VIVO – career day at NTNU on January 22 2015.
The board of Targovax is pleased to announce Mr. Gunnar Gårdemyr as the new CEO from January 12th, 2015.
Oslo Cancer Cluster member BerGenBio AS announces first patient dosed in its multi-centre Phase 1b trial of BGB324 in patients with acute myeloid leukaemia at Haukeland.
Oslo Cancer Cluster member Targovax AS has reached an important milestone in clinical trial phase I/II.
Almost 350 students at Oslo and Akershus University College of Applied Sciences was engaged in last weeks Innovation Camp where they were asked to come up with original ideas on how to communicate personalized cancer medicine.
Oslo Cancer Cluster would like to welcome our four new members on board: DNB Bank, Oslo and Akershus University College: Faculty of Health Sciences, Scandinavian Development Services and Prostataklinikken.
Contact us >
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.